Given the small numbers of patients, we had too little power to confirm or refute ER status findings from Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer.24 Similarly, the number of patients with leptomeningeal disease was too small to draw firm conclusions. Here, ERBB2 is linked to breast carcinoma.